Stealth BioTherapeutics Corp MITO
0.32 0.00 (+0.00%)
At closeNov 15, 2022, 4:00 PM EST
0.32 Day range 0.33
52-week range unavailable
Analyst view
Consensus: buy
Buy
Price target (mean) 1.77 +453.1% upside
Now 0.32
- Target (low)
- 1.50
- Target (mean)
- 1.77
- Target (high)
- 2.05
Ratings (-1m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 1
- 2 months ago 1
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.02 | -0.03 – -0.01 | -0.01 | -100.0% | 0 | 0.0% | 2 |
| Next quarter | -0.01 | -0.01 – -0.01 | -0.03 | +66.7% | 0 | 0.0% | 2 |
| Current year | -0.06 | -0.07 – -0.05 | -0.08 | +25.0% | 0 | 0.0% | 2 |
| Next year | -0.05 | -0.06 – -0.04 | -0.06 | +16.7% | 0 | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 23, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Jul 1, 2021 | Maxim Group | Initiated | — | Buy |
| Apr 3, 2020 | Nomura | Maintained | — | Buy |
| Apr 2, 2020 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Dec 23, 2019 | H.C. Wainwright | Downgrade | Buy | Neutral |
| Sep 27, 2019 | Cantor Fitzgerald | Initiated | — | Overweight |
| Jun 18, 2019 | H.C. Wainwright | Initiated | — | Buy |
| Mar 12, 2019 | Nomura | Initiated | — | Buy |
| Mar 12, 2019 | BMO Capital | Initiated | — | Outperform |